Crosslink Therapeutics key facts
- Operator of a biologics platform intended to enable targeted cancer treatment using tumor-specific biochemical markers.
- It has raised $8.0M across 1 recorded rounds; the latest was Seed Round ($4.3M) in Apr 2025.
- Notable investors include Highlight Capital, TIFF Investment Management, Cure Ventures, Rivas Capital, Sigmas Group.
- Crosslink Therapeutics has filed 1 Form D with the SEC, most recently May 2025 ($4.3M sold to 6 investors).
- Status: Privately Held (backing).
Who backs Crosslink Therapeutics
5- ·Watch Crosslink Therapeutics: the Monday email on marks, rounds and moves
Crosslink Therapeutics funding rounds
1 roundsHow much has Crosslink Therapeutics raised?
Crosslink Therapeutics has raised $8 million in total; 1 of its rounds is on record. The largest on record was a $4.3 million seed round in Apr 2025.
Crosslink Therapeutics has filed 1 Form D with the SEC, most recently in May 2025 ($4.3 million sold to 6 investors).
Crosslink Therapeutics investors
5 investors are on record for Crosslink Therapeutics, including Highlight Capital, TIFF Investment Management, Cure Ventures and Rivas Capital. The seed round in Apr 2025 drew 6 investors.
About Crosslink Therapeutics
Operator of a biologics platform intended to enable targeted cancer treatment using tumor-specific biochemical markers. The company offers a modular biologic domain that assembles therapeutics in the presence of elevated extracellular ATP and can be applied across antibody drug conjugates and radioligand therapies, enabling oncology researchers and pharmaceutical developers to achieve improved tumor targeting and therapeutic effectiveness.
- Sector
- Healthcare
- HQ
- Boston, MA, United States
- Founded
- 2022
- Employees
- 4
- Website
- xlinktx.com/
- Ownership
- Privately Held (backing)
Is this your company? Sign in with your work email to keep it current, or tell us what's wrong.
Crosslink Therapeutics doesn't have a valuation on record yet — one is published once a priced round, a reported valuation, fund marks, or secondary prints surface in our sources. The rest of the record below builds toward it.